PROTECH BIOSYSTEMS GROUP For a Healthy Today…

Protech Group at a glance $ 20mn+ Total Revenue Countries Registered Products Dosage Forms Therapeutic Categories Manufacturing Facilities Products Filling Future Expected Growth Protech Group at a glance 36 Protech group is one of the fastest growing Indian pharmaceutical group of company engaged in developing, manufacturing, exporting and marketing a broad range of pharmaceutical products globally. Year of company establishment 1998 Commercial presence in more than 36 countries. Protech is growing with vision to serve countries below poverty line with same quality products that are existing only in developed countries with mission to make our products available in all regulated markets by 2023 430 + 20 + 15 + 3 + 760 + 50-55 % +

Protech Group: Key differentiators Coherent capabilities spanning entire product development cycle Integrated capabilities from identifying high value opportunities to development to regulatory review to commercialization Solid track record of filings and approvals 100+ in Africa, 260+ in CIS and 400+ in eight South East Asian markets Solid track record of regulatory compliance Many successful inspections over the last few years. Continue to maintain strong track record in all Regulatory inspections. Diversified portfolio across Specialties and Pharma offers stability – Offers wide range of products covering Orals, Semi Solids and Specialty injectables including Beta-lactams, Cephalosporins, Oncolytics and Penems Partnership with Big Pharma Partnerships with pharmaceutical majors CIS,Africa, Asia and LATAM to boost up the demand and capture the market in strategic plan. Targeting products with significant demand Increasingly targets products that are in short supply ,near term patent expiries ,difficult to manufacture segments Significant investments completed in manufacturing facilities Significant investments completed in specialties space plants scectons will allow acceleration of developed markets strategy Focus on R&D Proven R&D capabilities for developed markets to meet the market needs and trends.

Growth Overview Sales Contribution: Protech entered in export business with CIS region and this region contributing 36% of total sales followed by Asia, Africa, LATAM and others. Growth Rate: Protech Biosystems Group is growing by 20% and organization planning to reach 50-55% growth year to year and more in coming 5 years.

Global Presence CIS ASIA LATAM AFRICA Russia Tajikistan Armenia Georgia Kazakhstan Kyrgyzstan Moldova Turkmenistan Uzbekistan Mongolia ASIA Phillipines Myanmar Srilanka Bhutan Cambodia Afghanistan Laos LATAM El-Salvador Bolivia Ecuador Uruguay Paraguay Guatemala Costa-rica Honduras Barbados AFRICA Botswana Mozambique Nigeria Ivory Coast Cameroon Zambia Ghana Rep of Guinea Mali

Prospects Countries CIS ASIA LATAM AFRICA Ukraine Malaysia Indonesia Thailand Vietnam Hong Kong LATAM Chile Argentina Perú Cuba AFRICA Ethiopia Tanzania Uganda Kenya Morocco Tunisia Egypt Protech Biosystems group is planning to start domestic business directly with own marketing team and with contract manufacturing

Protech Facility For Different Dosage Forms Tablets Capsules Liquid Orals Protech Facility For Different Dosage Forms Dry Powder for Injection Dry Syrup Liquid Injection Ointment, Cream and Gels

Business Strategy Sustainable Growth Continue growth of Cephalosporin , Anti- diabetic and Cardio vascular Business Strengthen Presence in Lifestyle Drugs Sustainable Growth Strong Corporate Governance Penetrate Regulated Markets Broad rang of Products Sustainability and increasing existing business 16

Strategy For Future Growth Penetrate in regulated market with prescription products New products development and filling capability Vibrant R&D, Manufacturing capability and Quality focus New facility for oncology products and entry in domestic market as well as international market with LVP, Lyophilized and prefilled syringe

Strategic Growth Plan R&D Process R&D is an important means for achieving future growth and maintaining a relevant product in the market globally. Protech Biosystems group has a strong and innovative research and development center, which had maid significant breakthrough in the development of various active pharmacological ingredients Research is continuously ongoing for the development and marketing of additional products Protech R&D team is working on new Oncology , Retro viral and Hepatitis products Protech Biosystems group has already proven abilities in process of innovative products development from time to time Many products are under development in R&D likely go off patent in regulated market which will substantially increase export sales in the next few years Ability to develop products with high technology barriers , foster ideas , prototype and trials. R&D Process Process R&D

Product Development and Filling Every year Protech develops new products as per market requirements to fulfill the unmet needs. New products development is increasing every year and it is helping to grow the business of Protech group globally. Protech has 430 Products registered in different 36 countries. Another 760 Products dossier are under registration in various countries on this day

Global Market Penetration Regulated Market 2018-19 ROW LATAM 2014 ASIA & AFRICA 2013 2010 CIS 2008 The journey of Protech started from 1998 with CIS region followed by ASIAN, AFRICAN, LATAM and ROW markets. Protech is Planning to make footprint in regulated market with prescription products Protech group has passed many international quality audits and received many international recognitions. Protech is planning to get the certifications of EU-GMP and PIC/S by the mid of 2019

Projection and Planning Planning for next 3 years ($ Mn) Region FY 2017-18 sale ($ Mn) Planning for next 3 years ($ Mn) CIS 7 9.8 ASIA 6 8.7 AFRICA 4.5 6.3 LATAM 2 3 ROW 1.5 2.2 Regulated Market - Domestic 5

Focus on distinctive core therapeutic segments R&D efforts focus on 3 Key Therapeutic segments : Oncology Products, CVS Products and Hepatitis-B Protech group is continuously working on oncology, CVS and other products like Hepatitis-B with highly qualified dedicated team and expecting to come up with new products in the market in next 1-2 years. Protech is working for different dosage form of the products Development Preapproval

Focus on distinctive core therapeutic segments Protech is targeting some specific countries for these new products of focused therapeutic segments- Latam: Ecuador, Guatemala, Chile, Argentina, Peru ,Cuba Africa: Egypt, Tunisia, Morocco, Ethiopia, Tanzania, Kenya, Nigeria, Ghana CIS: Russia, Tajikistan, Turkmenistan, Uzbekistan, Ukraine Asia: Phillipines, Srilanka, Malaysia, Indonesia, Thailand, Vietnam

Specialized products of Protech group Sodium Hyaluronate Prefilled Syringe Rasburicase Lyophilized Powder for Injection Leuprolide acetate microspheres depot Injection Vancomycin Hydrochloride Lyophilized Powder for Injection Cerebroprotein Hydolysate for Injection Papain - Urea Debriding Ointment in Lamitube Erythropoietin Prefilled Syringe Enoxaparin Sodium Prefilled Syringe Tetanus Toxoid Injection Plerixafor Injection

THANK YOU PROTECH BIOSYSTEMS GROUP Corporate Office Unit 314, 3rd Floor, Well done Tech Park, Sector-48, Sohna Road, Gurgaon- 122001, Haryana, India. Board  : +91-124-4516600 bd@protechbiosystem.com www.protechbiosystem.com